Accepted for Publication: July 21, 2022.
Published: September 7, 2022. doi:10.1001/jamanetworkopen.2022.30293
Correction: This article was corrected on October 6, 2022, to fix errors in Figure 2.
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Zhao LP et al. JAMA Network Open.
Corresponding Author: Lue Ping Zhao, PhD, Public Health Sciences Division (email@example.com), and Lawrence Corey, MD, Vaccine and Infectious Disease Division (firstname.lastname@example.org), Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109.
Author Contributions: Dr Zhao had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Zhao, Lybrand, Payne, Corey.
Acquisition, analysis, or interpretation of data: Zhao, Lybrand, Gilbert, Madeleine, Cohen, Geraghty, Jerome.
Drafting of the manuscript: Zhao, Lybrand, Payne.
Critical revision of the manuscript for important intellectual content: Zhao, Lybrand, Gilbert, Madeleine, Cohen, Geraghty, Jerome, Corey.
Statistical analysis: Zhao, Lybrand.
Obtained funding: Gilbert, Geraghty, Jerome, Corey.
Administrative, technical, or material support: Geraghty, Jerome.
Supervision: Payne, Cohen, Geraghty, Jerome, Corey.
Conflict of Interest Disclosures: Dr Gilbert reported grants from the National Institutes of Health National Institute of Allergy and Infectious Diseases for statistical work on COVID-19 vaccine efficacy trials during the conduct of the study. No other disclosures were reported.
Funding/Support: This research was funded by grants UM1 AI68614 and UM1 AI068635 from the National Institutes of Health National Institute of Allergy and Infectious Diseases.
Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Information: All sequence data analyzed here are publicly available at GISAID (https://www.gisaid.org/).
LP , Lybrand
TP , Gilbert
et al. Tracking SARS-CoV-2 spike protein mutations in the United States (2020/01 – 2021/03) using a statistical learning strategy. Viruses
. 2022;14(1):9. doi:10.3390/v14010009Google ScholarCrossref
T , Tibshirani
R . Generalized additive models. Stat Sci
. 1986;1(3):297-318.Google Scholar
LP , Roychoudhury
P , Gilbert
et al. Variants in nucleocapsid protein and endoRNase are found to associate with severe COVID-19 hospitalization risk in a case-control study in Washington State, USA. Sci Rep
. 2022;12:1206. doi:10.1038/s41598-021-04376-4Google ScholarCrossref